These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26851606)

  • 41. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.
    Peixoto F; Nascimento MT; Costa R; Silva J; Renard G; Guimarães LH; Penna G; Barral-Netto M; Carvalho LP; Machado PRL; Carvalho EM
    J Immunol Res; 2020; 2020():2789859. PubMed ID: 32851099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
    Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
    Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.
    Wege AK; Florian C; Ernst W; Zimara N; Schleicher U; Hanses F; Schmid M; Ritter U
    PLoS Negl Trop Dis; 2012; 6(7):e1741. PubMed ID: 22848771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repurposing topical triclosan for cutaneous leishmaniasis: Preclinical efficacy in a murine Leishmania (L.) amazonensis model.
    Mesquita JT; Romanelli MM; de Melo Trinconi Trinconi Cm C; Guerra JM; Taniwaki NN; Uliana SRB; Reimão JQ; Tempone AG
    Drug Dev Res; 2022 Apr; 83(2):285-295. PubMed ID: 32767443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K; Croft SL
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
    Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
    Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
    Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
    Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
    Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
    Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combinations of ascaridole, carvacrol, and caryophyllene oxide against Leishmania.
    Pastor J; García M; Steinbauer S; Setzer WN; Scull R; Gille L; Monzote L
    Acta Trop; 2015 May; 145():31-8. PubMed ID: 25697866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2'-Hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant Leishmania amazonensis.
    Gervazoni LFO; Gonçalves-Ozório G; Almeida-Amaral EE
    PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006930. PubMed ID: 30521527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
    Eissa MM; Amer EI; El Sawy SM
    Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Miltefosine to treat leishmaniasis.
    Berman J
    Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
    Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S
    Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.